Author

C. J. Pirozzi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 5 Research Focus:cell type annotation· 4 Organism:human· 4 Research Focus:differential expression· 3 Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Approach:statistical model· 2 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Y. He· 5 shared D. M. Ashley· 4 shared K. Roso· 4 shared R. Yang· 3 shared D. D. Bigner· 2 shared L. H. Chen· 2 shared M. A. Sun· 2 shared P. K. Greer· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

Y. He

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Gene expression analysis suggests immunosuppressive roles of endolysosomes in glioblastoma

M. A. Sun, H. Yao, Q. Yang, C. J. Pirozzi, V. Chandramohan, D. M. Ashley, Y. He

The paper analyzes gene expression in glioblastomas to show endolysosomes in non-tumor cells and immunosuppressive macrophages contribute to a pro-tumorigenic microenvironment.

bioRxiv · Aug 31, 2023Cancer Biology

Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas

S. Hariharan, B. T. Whitfield, C. J. Pirozzi, M. S. Waitkus, M. C. Brown, M. L. Bowie, D. M. Irvin, K. Roso, R. Fuller, J. Hostettler, S. Dharmaiah, E. A. Gibson, A. Briley, A. Mangoli, C. Fraley, , D. M. Ashley

This study shows that ATRX loss primes glioma cells for innate immune recognition, while IDH1R132H mutation suppresses immune signaling, which can be reversed by IDH1 inhibition.

bioRxiv · Apr 20, 2023 · PreprintCancer Biology

Repurposing clemastine to target glioblastoma cell stemness

M. A. Sun, R. Yang, H. Liu, W. Wang, X. Song, B. Hu, N. Reynolds, K. Roso, L. H. Chen, P. K. Greer, S. T. Keir, R. E. McLendon, S.-Y. Cheng, D. D. Bigner, D. M. Ashley, , Y. He

This study shows clemastine, an antihistamine, reduces glioblastoma stemness by targeting EBP, a cholesterol pathway enzyme, and promotes differentiation of oligodendrocyte progenitor cells.

bioRxiv · Nov 5, 2022 · PreprintCancer Biology

Inhibiting adenine synthesis attenuates glioblastoma cell stemness and temozolomide resistance

S. X. Singh, R. Yang, K. Roso, L. J. Hansen, C. Du, L. H. Chen, P. K. Greer, C. J. Pirozzi, Y. He

This study shows that inhibiting adenine synthesis with L-Alanosine reduces stemness and temozolomide resistance in MTAP-deficient glioblastoma cells by impairing mitochondrial function.

bioRxiv · Jun 21, 2021 · PreprintCancer Biology

Distribution and vulnerability of transcriptional outputs across the genome in Myc-amplified medulloblastoma cells

R. Yang, W. Wang, M. Dong, K. Roso, P. Greer, X. Bao, C. J. Pirozzi, D. D. Bigner, H. Yan, D. M. Ashley, F. Zou, V. Zhabotynsky, Y. He

This study examines the distribution of transcriptional outputs in Myc-amplified medulloblastoma cells and identifies IMPDHs as a therapeutic target.

bioRxiv · Jun 7, 2021 · PreprintCancer Biology